Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HH 2853

Next Previous
Drug Profile

HH 2853

Alternative Names: HH-2853

Latest Information Update: 23 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HaiHe Biopharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors; EZH1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Diffuse large B cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma; Soft tissue sarcoma

Most Recent Events

  • 09 Dec 2023 Efficacy and adverse events data from a phase-I trial in Peripheral T-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 15 Jun 2023 Haihe Biopharma completes a phase I trial in Peripheral T-cell lymphoma (Second-line therapy or greater) in China (PO)
  • 02 Jun 2023 Efficacy and adverse events data from phase-I/II trial in Soft tissue sarcoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top